Evidence map›Paper›PMID 34328586›Full record

ArticleJournal of computer-aided molecular design2021

Quantum simulations of SARS-CoV-2 main protease M

Yuhang Wang, Sruthi Murlidaran, David A Pearlman

Open access · bronzeAbstract read
In one paragraph

Article in Journal of computer-aided molecular design, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yuhang WangQuantum Simulation Technologies, Inc, 625 Massachusetts Ave, Floor 2, Cambridge, MA, 02139, USA.ORCID 0000-0003-3715-8349
Sruthi MurlidaranQuantum Simulation Technologies, Inc, 625 Massachusetts Ave, Floor 2, Cambridge, MA, 02139, USA.
David A PearlmanQuantum Simulation Technologies, Inc, 625 Massachusetts Ave, Floor 2, Cambridge, MA, 02139, USA. pearlman@qsimulate.com.ORCID 0000-0002-2574-6066
Simulation Technologies (United States) · US

Funding

Scoring ligand/protein interactions using a novel high performance implementation of DFT quantum mechanicsR43GM140578 · NIGMS · QUANTUM SIMULATION TECHNOLOGIES, INC. · PI PEARLMAN, DAVID A · 2021 to 2021
$147k
NIGMS NIH HHS R43 GM140578
6 · The paper itself

Abstract

The COVID-19 pandemic has led to unprecedented efforts to identify drugs that can reduce its associated morbidity/mortality rate. Computational chemistry approaches hold the potential for triaging potential candidates far more quickly than their experimental counterparts. These methods have been widely used to search for small molecules that can inhibit critical proteins involved in the SARS-CoV-2 replication cycle. An important target is the SARS-CoV-2 main protease Mpro, an enzyme that cleaves the viral polyproteins into individual proteins required for viral replication and transcription. Unfortunately, standard computational screening methods face difficulties in ranking diverse ligands to a receptor due to disparate ligand scaffolds and varying charge states. Here, we describe full density functional quantum mechanical (DFT) simulations of Mpro in complex with various ligands to obtain absolute ligand binding energies. Our calculations are enabled by a new cloud-native parallel DFT implementation running on computational resources from Amazon Web Services (AWS). The results we obtain are promising: the approach is quite capable of scoring a very diverse set of existing drug compounds for their affinities to M pro and suggest the DFT approach is potentially more broadly applicable to repurpose screening against this target. In addition, each DFT simulation required only ~ 1 h (wall clock time) per ligand. The fast turnaround time raises the practical possibility of a broad application of large-scale quantum mechanics in the drug discovery pipeline at stages where ligand diversity is essential.

Indexed as

Antiviral AgentsAtazanavir SulfateBinding SitesCloud ComputingCoronavirus 3C ProteasesDensity Functional TheoryHydrogen BondingLigandsMolecular Docking SimulationProtein ConformationQuantum Theory3C-like proteinase, SARS-CoV-2Antiviral AgentsAtazanavir SulfateCoronavirus 3C ProteasesLigandsCOVID-19Density Functional TheoryDiscoveryDrug triageQuantum mechanicsSARS-CoV-2 Mpro

Identifiers

PMID34328586
PMCPMC8321885
OpenAlexW3093100312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.